Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director · President & CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,627 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 418 · Balance 54,627 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 28 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 43,334 | $83.65 | $3,624,889.10 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,147 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.60 to $84.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 01, 2018 Filed May 4, 2018 00:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 43,334 | $10.69 | $463,240.46 |
DisclosureSEC source: 0001209191-18-027941 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for options expiring in the next 12 months. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 00:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 12,788 | $82.94 | $1,060,636.72 |
DisclosureSEC source: 0001209191-18-011597 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,147 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,333 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-18-005221 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,333 | $75.82 | $6,318,308.06 |
DisclosureSEC source: 0001209191-18-005221 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,935 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.39 to $79.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,333 | $11.34 | $944,996.22 |
DisclosureSEC source: 0001209191-18-005221 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 151,250 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-17-066485 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,250 Underlying: Common Stock · 151,250 shares Expires 2025-12-14 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 60,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066485 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,935 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,333 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-066050 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,333 | $55.69 | $4,640,814.77 |
DisclosureSEC source: 0001209191-17-066050 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,435 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.26 to $56.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,333 | $11.34 | $944,996.22 |
DisclosureSEC source: 0001209191-17-066050 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 18,069 | $44.23 | $799,191.87 |
DisclosureSEC source: 0001209191-17-061596 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,435 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 137,500 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001209191-17-061596 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2024-12-12 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016). F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI). F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061596 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,504 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI). Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,334 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-059310 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 83,334 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,334 | $23.57 | $1,964,182.38 |
DisclosureSEC source: 0001209191-17-059310 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,504 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.96 to $24.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,334 | $11.34 | $945,007.56 |
DisclosureSEC source: 0001209191-17-059310 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,333 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-056534 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 83,333 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,333 | $24.20 | $2,016,658.60 |
DisclosureSEC source: 0001209191-17-056534 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,504 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.77 to $24.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,333 | $11.34 | $944,996.22 |
DisclosureSEC source: 0001209191-17-056534 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,333 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-052127 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,333 Underlying: Common Stock · 83,333 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,333 | $21.54 | $1,794,992.82 |
DisclosureSEC source: 0001209191-17-052127 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,504 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.09 to $21.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,333 | $11.34 | $944,996.22 |
DisclosureSEC source: 0001209191-17-052127 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 83,334 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-049668 · doc4.xml · derivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,666 Underlying: Common Stock · 83,334 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 83,334 | $19.25 | $1,604,179.50 |
DisclosureSEC source: 0001209191-17-049668 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,504 F3 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.02 to $19.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 83,334 | $11.34 | $945,007.56 |
DisclosureSEC source: 0001209191-17-049668 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 related to 500,000 stock options scheduled to expire on January 31, 2018. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,380 | $19.32 | $161,901.60 |
DisclosureSEC source: 0001209191-17-049668 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,504 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.02 to $19.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 16, 2017 Filed May 19, 2017 00:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,388 | $19.55 | $163,985.40 |
DisclosureSEC source: 0001209191-17-033771 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,884 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.31 to $19.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2017 Filed Feb 18, 2017 01:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,636 | $13.14 | $113,477.04 |
DisclosureSEC source: 0001209191-17-012408 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,272 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.94 to $13.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 01:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 87,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0000899243-17-003646 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 01:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 87,500 | $13.04 | $1,141,000.00 |
DisclosureSEC source: 0000899243-17-003646 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,908 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.71 to $13.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 01:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 87,500 | $4.65 | $406,875.00 |
DisclosureSEC source: 0000899243-17-003646 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 87,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-17-004689 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 87,500 | $12.35 | $1,080,625.00 |
DisclosureSEC source: 0001209191-17-004689 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,908 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.19 to $12.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 87,500 | $4.65 | $406,875.00 |
DisclosureSEC source: 0001209191-17-004689 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 137,500 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-16-155521 · doc4.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2024-12-12 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155521 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,908 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 87,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-16-154514 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 87,500 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 87,500 | $12.24 | $1,071,000.00 |
DisclosureSEC source: 0001209191-16-154514 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,908 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.02 to $12.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 87,500 | $4.65 | $406,875.00 |
DisclosureSEC source: 0001209191-16-154514 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 87,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-16-151305 · doc4.xml · derivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 87,500 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 87,500 | $13.87 | $1,213,625.00 |
DisclosureSEC source: 0001209191-16-151305 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,908 F2 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.71 to $13.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 87,500 | $4.65 | $406,875.00 |
DisclosureSEC source: 0001209191-16-151305 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,958 | $13.96 | $83,173.68 |
DisclosureSEC source: 0001209191-16-151305 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,908 F1 · price: This transaction was executed in multiple trades at prices ranging from $13.71 to $14.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 21:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 87,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-16-145266 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 87,500 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 21:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 87,500 | $17.06 | $1,492,750.00 |
DisclosureSEC source: 0001209191-16-145266 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,866 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.82 to $17.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 21:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 87,500 | $4.65 | $406,875.00 |
DisclosureSEC source: 0001209191-16-145266 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.